{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T14:15:06Z","timestamp":1763388906488,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.cllc.2014.06.009","type":"journal-article","created":{"date-parts":[[2014,8,15]],"date-time":"2014-08-15T14:03:11Z","timestamp":1408111391000},"page":"455-465","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Correlation Between TS, MTHFR, and ERCC1 Gene Polymorphisms and the Efficacy of Platinum in Combination With Pemetrexed First-Line Chemotherapy in Mesothelioma Patients"],"prefix":"10.1016","volume":"15","author":[{"given":"Tomasz","family":"Powr\u00f3zek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dariusz M.","family":"Kowalski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawe\u0142","family":"Krawczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodryg","family":"Ramlau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Kucharczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Kalinka-Warzocha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Knetki-Wr\u00f3blewska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinga","family":"Winiarczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech","family":"Dyszkiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej","family":"Krzakowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janusz","family":"Milanowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2014.06.009_bib1","first-page":"1433","article-title":"Malignant mesothelioma","volume":"29","author":"Ahmed","year":"2013","journal-title":"Pak J Med Sci"},{"key":"10.1016\/j.cllc.2014.06.009_bib2","first-page":"508","article-title":"Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future","volume":"1","author":"Nowak","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"key":"10.1016\/j.cllc.2014.06.009_bib3","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1510\/icvts.2005.123430","article-title":"The MARS trial: mesothelioma and radical surgery","volume":"5","author":"Treasure","year":"2006","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"10.1016\/j.cllc.2014.06.009_bib4","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 14","key":"10.1016\/j.cllc.2014.06.009_bib5","article-title":"Pemetrexed in combination with cisplatin in the treatment of chemonaive patients with malignant pleural mesothelioma (MPM): outcomes on Expanded Access Program (EAP) (abstract)","volume":"22","author":"Wozniak","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2014.06.009_bib6","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1158\/1535-7163.MCT-06-0343","article-title":"Pemetrexed: biochemical and cellular pharmacology","volume":"6","author":"Chattopadhyay","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.cllc.2014.06.009_bib7","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/jnci\/94.14.1091","article-title":"An analysis of DNA repair as a determinant of survival in patients with non\u2013small-cell lung cancer","volume":"94","author":"Bosken","year":"2002","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.cllc.2014.06.009_bib8","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10637-007-9060-9","article-title":"In\u00a0vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression","volume":"25","author":"Hanauske","year":"2007","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.cllc.2014.06.009_bib9","doi-asserted-by":"crossref","first-page":"13790","DOI":"10.1073\/pnas.191502998","article-title":"Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses","volume":"98","author":"Bhattacharjee","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cllc.2014.06.009_bib10","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1002\/cncr.22208","article-title":"Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase","volume":"107","author":"Ceppi","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2014.06.009_bib11","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1634\/theoncologist.2008-0232","article-title":"The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies","volume":"14","author":"Scagliotti","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.cllc.2014.06.009_bib12","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1247\/csf.20.191","article-title":"Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5-termial regulatory region of the human gene for thymidylate synthase","volume":"20","author":"Horie","year":"1995","journal-title":"Cell Struct Funct"},{"key":"10.1016\/j.cllc.2014.06.009_bib13","first-page":"2898","article-title":"A\u00a0novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity","volume":"63","author":"Mandola","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.cllc.2014.06.009_bib14","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/00008571-200405000-00007","article-title":"A\u00a06-bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels","volume":"14","author":"Mandola","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.cllc.2014.06.009_bib15","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/ng0595-111","article-title":"A\u00a0candidate risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase","volume":"10","author":"Frosst","year":"1995","journal-title":"Nat Genet"},{"key":"10.1016\/j.cllc.2014.06.009_bib16","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.3892\/or.2013.2696","article-title":"Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non\u2013small-cell lung cancer patients","volume":"30","author":"Mlak","year":"2013","journal-title":"Oncol Rep"},{"key":"10.1016\/j.cllc.2014.06.009_bib17","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1054\/bjoc.2001.2007","article-title":"A\u00a0polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil","volume":"85","author":"Iacopetta","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cllc.2014.06.009_bib18","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1200\/JCO.2005.03.5253","article-title":"Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment","volume":"24","author":"Dotor","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2014.06.009_bib19","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1158\/1078-0432.CCR-10-2873","article-title":"Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed\/carboplatin","volume":"17","author":"Zucali","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2014.06.009_bib20","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1200\/JCO.2005.04.3190","article-title":"Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma","volume":"24","author":"Ceresoli","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2014.06.009_bib21","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/annonc\/mdm501","article-title":"Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM)","volume":"19","author":"Castagneto","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2014.06.009_bib22","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/JTO.0b013e31817c73d6","article-title":"Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: result of the International Expanded Access Program","volume":"3","author":"Santoro","year":"2008","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2014.06.009_bib23","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomized feasibility study","volume":"12","author":"Treasure","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2014.06.009_bib24","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/annonc\/mdi187","article-title":"Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma","volume":"16","author":"Manegold","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2014.06.009_bib25","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.lungcan.2011.08.011","article-title":"Second-line chemotherapy in malignant pleural mesothelioma: result of retrospective multicenter survey","volume":"75","author":"Zucali","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2014.06.009_bib26","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1097\/JTO.0b013e318293e45b","article-title":"\u201cOne marker does not fit all\u201d: additional translation and validation studies are needed to identify faithful predictors of pemetrexed activity in mesothelioma","volume":"8","author":"Giovanett","year":"2013","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2014.06.009_bib27","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1093\/annonc\/mdq253","article-title":"New tricks for old biomarkers: thymidylate synthase expression as a predictor of pemetrexed activity in malignant mesothelioma","volume":"21","author":"Zucali","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2014.06.009_bib28","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1200\/JCO.2009.25.9275","article-title":"Thymidylate synthase but not excision repair cross-complemention group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy","volume":"20","author":"Righi","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2014.06.009_bib29","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1007\/s11033-014-3197-3","article-title":"Thymidylate synthase polymorphisms are\u00a0associated to therapeutic outcome of advanced non-small cell lung cancer patients treated with platinum-based chemotherapy","volume":"41","author":"Lima","year":"2014","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.cllc.2014.06.009_bib30","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s12032-010-9443-1","article-title":"Predictive value of ERCC1 and XPD polymorphism in patients with advanced non\u2013small-cell lung cancer receiving platinum-based chemotherapy: a systemic review and meta-analysis","volume":"28","author":"Wei","year":"2011","journal-title":"Med Oncol"},{"key":"10.1016\/j.cllc.2014.06.009_bib31","doi-asserted-by":"crossref","first-page":"7230","DOI":"10.1200\/JCO.2005.02.0495","article-title":"Studying the predictive\/prognostic role of thymidylate synthase genotypes in patients with colorectal cancer: is one polymorphism enough?","volume":"23","author":"Grazziano","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2014.06.009_bib32","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/annonc\/mdr324","article-title":"The influence of platinum pathway polymorphisms on the outcome in patients with malignant mesothelioma","volume":"23","author":"Erculi","year":"2012","journal-title":"Ann Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730414001429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730414001429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:04:44Z","timestamp":1761505484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730414001429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S1525730414001429"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2014.06.009","relation":{},"ISSN":["1525-7304"],"issn-type":[{"type":"print","value":"1525-7304"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Correlation Between TS, MTHFR, and ERCC1 Gene Polymorphisms and the Efficacy of Platinum in Combination With Pemetrexed First-Line Chemotherapy in Mesothelioma Patients","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2014.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}